October 02, 2019
Article
Clinical Viewpoint
Despite early reservations, available literature suggests that it may be time to invest in the utilization of wellness-based methods in the treatment of migraine.
October 01, 2019
Article
Clinical Viewpoint
New classes of acute migraine therapies on the cusp of FDA approval look to fill in long-standing gaps in care.
September 30, 2019
Article
Pathways
After a long period of time with minimally effective treatments for migraine, the growing understanding of the CGRP pathway has opened the door to a variety of new and highly efficacious therapies for patients with chronic and episodic forms of disease.
September 28, 2019
Article
Clinical Viewpoint
Reproductive considerations and hormonal fluctuations throughout a woman’s life require careful consideration when treating migraine.
September 26, 2019
Article
Clinical Viewpoint
Reducing the frequency of migraine is only 1 step in the process of optimizing management and addressing the disease's impact on patients’ lives.
Evusheld Increased Attenuated SARS-CoV-2 Antibodies From MS B-Cell Depleting Medications
NeurologyLive® Friday 5 — June 24, 2022
Exploiting Anti-CD3 Antibodies, Relevant Biomarkers in Progressive MS: Tanuja Chitnis, MD
FDA Places Clinical Hold on Duchenne Muscular Dystrophy Drug SRP-5051 Amid Safety Concerns